These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. Shi X; Yao D; Gosnell BA; Chen C J Lipid Res; 2012 Nov; 53(11):2318-30. PubMed ID: 22904346 [TBL] [Abstract][Full Text] [Related]
30. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Chen Y; Zhou J; Xu S; Liu M; Wang M; Ma Y; Zhao M; Wang Z; Guo Y; Zhao L Biochem Pharmacol; 2019 Dec; 170():113669. PubMed ID: 31628911 [TBL] [Abstract][Full Text] [Related]
31. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Kohjima M; Enjoji M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Fujino T; Yada M; Yada R; Harada N; Takayanagi R; Nakamuta M Int J Mol Med; 2007 Sep; 20(3):351-8. PubMed ID: 17671740 [TBL] [Abstract][Full Text] [Related]
32. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Tang W; Borel AG; Fujimiya T; Abbott FS Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749 [TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. Fischer M; You M; Matsumoto M; Crabb DW J Biol Chem; 2003 Jul; 278(30):27997-8004. PubMed ID: 12791698 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of peroxisome proliferator-activated receptor-alpha (PPARalpha)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-oxidation system. Jia Y; Qi C; Zhang Z; Hashimoto T; Rao MS; Huyghe S; Suzuki Y; Van Veldhoven PP; Baes M; Reddy JK J Biol Chem; 2003 Nov; 278(47):47232-9. PubMed ID: 14500732 [TBL] [Abstract][Full Text] [Related]
35. Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity. Xu S; Chen Y; Ma Y; Liu T; Zhao M; Wang Z; Zhao L Front Pharmacol; 2019; 10():819. PubMed ID: 31379584 [TBL] [Abstract][Full Text] [Related]
36. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. Hashimoto T; Fujita T; Usuda N; Cook W; Qi C; Peters JM; Gonzalez FJ; Yeldandi AV; Rao MS; Reddy JK J Biol Chem; 1999 Jul; 274(27):19228-36. PubMed ID: 10383430 [TBL] [Abstract][Full Text] [Related]
37. Regulation of energy metabolism by long-chain fatty acids. Nakamura MT; Yudell BE; Loor JJ Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249 [TBL] [Abstract][Full Text] [Related]
38. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Lee MH; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO Toxicol Appl Pharmacol; 2008 Feb; 226(3):271-84. PubMed ID: 17963808 [TBL] [Abstract][Full Text] [Related]
39. Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin. Granit A; Mishra K; Barasch D; Peretz-Yablonsky T; Eyal S; Kakhlon O Front Cell Dev Biol; 2022; 10():1014798. PubMed ID: 36544904 [TBL] [Abstract][Full Text] [Related]